![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Financial Bull 3X Shares ETF
FAS
SPDR S&P Retail ETF
XRT
4
iShares US Home Construction ETF
ITB
5
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
US Stock MarketDetailed Quotes
Glaukos (GKOS)
- 126.810
- +2.550+2.05%
Close Jun 12 15:59 ET
- 126.810
- 0.0000.00%
Post 20:01 ET
7.45BMarket Cap-38.43P/E (TTM)
128.270High122.690Low707.98KVolume124.970Open124.260Prev Close89.79MTurnover1.23%Turnover RatioLossP/E (Static)58.73MShares148.11052wk High11.10P/B7.32BFloat Cap73.16052wk Low--Dividend TTM57.74MShs Float163.710Historical High--Div Yield TTM4.49%Range %14.250Historical Low126.825Avg Price1Lot Size
GKOS Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
GKOS Orderflow
Unit: --
GKOS Orderflow Trend
IntradayDayWeekMonth
No Data
Glaukos (GKOS) News
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $162
Express News | Citigroup Maintains Buy on Glaukos, Raises Price Target to $162
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $162
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $170
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $162
Needham Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $136
Glaukos (GKOS) Stock Forum
Glaukos' revenue growth is the market's focus due to its unprofitability. The 88% share price gain is solid, not standout. Market sentiment is lukewarm, hinting at potential stronger growth trends. Recent sentiment is positive due to strong share price momentum.
Last week’s PDUFAs:
$Arcutis Biotherapeutics (ARQT.US)$ :![]()
Approved 12/15
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15![]()
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14![]()
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...
$Arcutis Biotherapeutics (ARQT.US)$ :
• ZORYVE® (Roflumilast foam 0.3%)
⇒ topical foam
⇒ PDUFA: 12/16/23
⇒ NDA
⇒ Seborrheic dermatitis
$Merck & Co (MRK.US)$ : Approved 12/15
• KEYTRUDA (pembrolizumab) + Padcev (enfortumab vedotin-ejfv)
⇒ IV injection
⇒ PDUFA: 05/09/24
⇒ sBLA
⇒ Urothelial cancer
$Glaukos (GKOS.US)$ : Approved 12/14
• iDose® TR (travoprost)
⇒ intracameral implant
⇒ PDUFA: 12/22/23
⇒ NDA
⇒ Glaucoma
$Merck & Co (MRK.US)$ : Approved ...
7
1
The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose(Delisted) (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio(Delisted) (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$
Join us to connect and share, and to get info fast!
$CRISPR Therapeutics (CRSP.US)$ $Vertex Pharmaceuticals (VRTX.US)$ $OptiNose(Delisted) (OPTN.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $Calliditas Therapeutics (CALT.US)$ $bluebird bio(Delisted) (BLUE.US)$ $Glaukos (GKOS.US)$ $Ionis Pharmaceuticals (IONS.US)$ $Amgen (AMGN.US)$ $Merck & Co (MRK.US)$
7
2
1
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)